TCR2 Therapeutics Inc., an immuno-oncology company developing the next generation of novel T cell therapies for treatment of patients with cancer, recently announced that it has entered into a CRADA (Cooperative Research and Development Agreement) with the NCI (National Cancer Institute) for partnering on the use of proprietary TCR T cell receptor TRuC-T cells (Fusion Construct T cells) of TCR2 Therapeutics, for treating cancer against mesothelin in its ongoing Phase 1/2 trial of TC-210.
Reportedly, the collaboration with the TGBM (Thoracic & GI Malignancies Branch) at National Cancer Institute, led by Dr. Raffit Hassan, TCR² Therapeutics will have access to extensive laboratory & clinical expertise of Thoracic & GI Malignancies Branch to treat patients with advanced mesothelin cancers.
For the record, in studies conducted by Dr. Hassan & his colleagues, they have confirmed mesothelin as a target for cancer therapy, categorizing mesothelin expression in different tumor types, which led to the progress of diagnostic analyses that measure shed mesothelin in serum along with further outlining the biological functions of mesothelin.
Garry Menzel, President & CEO of TCR2 Therapeutics was reported to state that the use of mesothelin as a target in immunotherapy and its fundamental confirmation by Dr. Hassan & his colleagues, was a major development in the field of oncology and the company is elated to collaborate with the NCI on the first clinical trial of TRuC-T cell against mesothelin.
He added, saying that the company is looking forward to providing an update on the efficacy, safety & translational studies taking place at several sites from the Phase 1 portion of the Phase 1/2 trial for TC-210.
As per the terms of the agreement, National Cancer Institute will be a participant in the Phase 1/2 clinical trial of TC-20 conducted by TCR2, to measure the potential of the company’s proprietary mesothelin-specific T cell-based therapy and for a better understanding of its pharmacodynamics.